Reply from Gilead (GILD)

I told them to take a look at immuron´s very attractive programs targeting fatty liver disease for a potential in-licensing of the drug or maybe to takeover the whole company (see Gilead´s answer below ) . I send more emails to Biotechs which focusing on Nash/Ash like Sanofi ,Intercept,Genfit and Allergan . Drug Deal could push this stock to $1.20-1.80 and buyout to minimum $2.50++ at this time . GL
---------------

Thank you for the email,xxxxx. GILD has a number of programs in the clinic that are focusing on liver diseases such as NASH.
On our recent earnings call, management mentioned it is interested in acquisitions and actively looking at options. I appreciate your suggestion.

Thank you.
Mark